GEOS vs DMAC Comparison

Geospace Technologies Corp is engaged in designing and manufacturing seismic instruments and non-seismic equipment used in the oil and gas industry. The company has three different segments: oil and gas markets, adjacent markets, and emerging markets. The oil and gas markets segment, which accounts for the majority of the company's revenue, includes traditional exploration products, wireless exploration products, and reservoir characterization products and services. The adjacent markets business is closely tied to the oil and gas markets and includes imaging products and industrial products. The company operates globally across Asia, Canada, Europe, the United States, South America, Mexico, and other regions with a majority of its revenue being generated within the United States.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.